Researchers developed a gene therapy that restored normal brain activity and improved behavior in mice with Fragile X syndrome by replacing the missing FMRP protein. The treatment administered during early development showed significant improvements in cognitive flexibility, social interactions, and probabilistic reversal learning.
SourceUniversity of California - Riverside·JournalMolecular Therapy — Nucleic Acids·TypeExperimental study·DateJun 18, 2026
Scientists have identified a new drug target for treating Fragile X syndrome by blocking the EPAC2 brain protein, which improves abnormal brain activity and behavioral symptoms. The study uses genetically engineered mice to simulate the condition and finds that EPAC2 levels rise gradually as the brain matures.
SourceUniversity of California - Los Angeles Health Sciences·JournalNeuron·DateMay 18, 2026
Researchers from the Salk Institute found that astrocytes play a crucial role in fragile X syndrome symptoms. Correcting dysregulations in star-shaped brain cells improved some symptoms, including reduced seizures and restored molecular balances in a mouse model of FXS. The study validates the importance of studying astrocytes in FXS r...
SourceSalk Institute·JournalNature Communications·DateApr 23, 2026
Researchers used base editing to correct the SCN8A gene mutation responsible for severe inherited epilepsy. The approach successfully eliminated or reduced seizures and improved brain function in lab mice, offering new hope for treating genetic epilepsies.
SourceUniversity of Virginia Health System·JournalJournal of Clinical Investigation·DateApr 7, 2026
Apple iPhone 17 Pro
Apple iPhone 17 Pro delivers top performance and advanced cameras for field documentation, data collection, and secure research communications.
Researchers have discovered a novel biomarker for fragile X syndrome in both human patients and mouse models, allowing for the comparison of brain wave patterns between species. This breakthrough enables the development of more effective treatments by enabling non-invasive treatment efficacy readouts across species.
SourcePicower Institute at MIT·JournalNature Communications·TypeExperimental study·DateFeb 11, 2026
Researchers found that abundant mRNA molecules tend to cluster together in brain neurons, driven by chance overlap rather than coordinated movement. This discovery provides insights into how neurons manage genetic instructions and supports learning and memory, with potential implications for conditions like Fragile X syndrome.
SourceVirginia Tech·JournaleNeuro·TypeExperimental study·DateDec 15, 2025
Researchers at UC Davis MIND Institute recommend testing for specific groups, citing inadequate recognition by healthcare providers. The group of genetic conditions affects learning, development, and behavior, with millions of people unaware they carry the premutation.
SourceUniversity of California - Davis Health·JournalNew England Journal of Medicine·DateJul 18, 2025
Researchers have identified a previously unknown organelle called the hemifusome that plays a crucial role in cellular sorting and recycling. This discovery could lead to targeted treatments for complex genetic disorders like Hermansky-Pudlak syndrome, which affects multiple systems in the body.
SourceUniversity of Virginia Health System·JournalNature Communications·DateJun 25, 2025
Researchers found that bumetanide treatment normalizes neonatal social communication in newborn pups with the fragile X mutation, but reduces post-pubertal social interaction. The study suggests stage-specific effects on social development and raises questions about timing and dosing of bumetanide for targeted interventions.
SourceGenomic Press·JournalGenomic Psychiatry·DateDec 24, 2024
SAMSUNG T9 Portable SSD 2TB
SAMSUNG T9 Portable SSD 2TB transfers large imagery and model outputs quickly between field laptops, lab workstations, and secure archives.
Fragile X-associated tremor/ataxia syndrome (FXTAS) is a severe condition affecting individuals with FMR1 gene mutations. A new study aims to understand which premutation carriers will develop FXTAS during middle or later adulthood and how it can be identified earlier.
The study analyzed the genetic profiles of 80,000 people and found that repeat expansion disorders (REDs) are common across different populations. The findings suggest a significant shift in how we think about genetic testing, profiling, and counseling for these conditions.
SourceQueen Mary University of London·JournalNature Medicine·TypeObservational study·DateOct 1, 2024
Research on mouse models reveals that CBD and metformin can alleviate repetitive behaviour, impaired speech, and learning impairments associated with these genetic conditions. The study also explores the potential for broader use of these treatments in autism spectrum disorder-related conditions.
SourceFederation of European Neuroscience Societies·TypeExperimental study·DateJun 25, 2024
Researchers found a bias in X-chromosome inactivation that protects females from harmful mutations linked to autism. The study suggests the paternal X chromosome is inactivated in 60% of cells, preventing mutation effects.
SourceUniversity of Washington School of Medicine/UW Medicine·JournalCell Reports·TypeExperimental study·DateApr 26, 2024
Researchers at UW-Madison discovered that FMRP regulates mitochondrial function in human brain cells even before birth, leading to a potential treatment for FXS. The study suggests that FMRP plays a critical role in prenatal development and may be linked to autism spectrum disorder.
SourceUniversity of Wisconsin-Madison·JournalNeuron·DateOct 10, 2023
Sky & Telescope Pocket Sky Atlas, 2nd Edition
Sky & Telescope Pocket Sky Atlas, 2nd Edition is a durable star atlas for planning sessions, identifying targets, and teaching celestial navigation.
Research finds that 75% of boys with fragile X meet criteria for co-occurring autism, but only 31% are identified in community settings. Early diagnosis is crucial to access services improving outcomes and quality of life.
SourceArnold School of Public Health·JournalResearch on Child and Adolescent Psychopathology·DateAug 29, 2023
Researchers are studying the characteristics of fragile X-associated tremor ataxia syndrome (FXTAS), aiming to develop treatments for this debilitating condition. The study focuses on understanding the phenotype of FXTAS, including its progression and impact on males and females.
SourceUniversity of California - Davis Health·DateJul 19, 2023
Researchers boosted inhibitory interneuron activity in Fragile X mice, reducing hypersensitivity to sensory stimuli. The study found that even young mice with Fragile X had lower PV neuron density and functional decoupling, but treatment restored excitatory neuron function and reduced hypersensitivity.
SourceUniversity of California - Los Angeles Health Sciences·JournalNeuron·DateJul 13, 2023
A novel antisense therapy has restored fragile X protein production in human cell samples, revealing aberrant alternative splicing of messenger RNA as a key factor in fragile X syndrome. This finding offers real hope for developing new treatments and improving the lives of individuals affected by the condition.
SourceUMass Chan Medical School·JournalProceedings of the National Academy of Sciences·TypeExperimental study·DateJul 5, 2023
Sony Alpha a7 IV (Body Only)
Sony Alpha a7 IV (Body Only) delivers reliable low-light performance and rugged build for astrophotography, lab documentation, and field expeditions.
A UC Riverside study identifies how a Fragile X gene mutation contributes to premature ovarian failure, leading to early infertility. Researchers found that the mutation affects neurons regulating reproduction in the brain and ovaries, causing an increase in hormone production and faster secretion rates.
SourceUniversity of California - Riverside·JournalFrontiers in Endocrinology·TypeExperimental study·DateApr 4, 2023
Researchers found that the NIH Toolbox Cognition Battery is a promising option for measuring cognitive change in people with intellectual disability. The study shows that the test is sensitive to developmental changes in children, teens, and young adults, which can help guide effective interventions.
SourceUniversity of California - Davis Health·JournalNeurology·DateDec 5, 2022
Researchers identified critical period plasticity in the amygdala that can be treated with therapeutic intervention at key developmental time points. Early pharmacological intervention was shown effective in reducing fear-learning in the mouse model.
SourceUniversity of Colorado Anschutz Medical Campus·JournalNeuroscience·DateSep 1, 2022
Researchers identified a molecule produced by astrocytes that interferes with normal neuron development in Rett, fragile X and Down syndromes. Blocking this molecule reduces disease signs in mice brains, suggesting potential therapeutics to treat these disorders.
SourceSalk Institute·JournalNature Neuroscience·DateAug 30, 2022
Researchers have discovered that inhibiting AKT, a key player in cell growth and survival, also decreases nonsense-mediated mRNA decay (NMD) in cells with fragile X syndrome. This finding provides new direction for developing treatments for the disorder and highlights the potential of existing drugs like Afuresertib.
SourceUniversity of Rochester Medical Center·JournalMolecular Cell·DateJun 28, 2022
Davis Instruments Vantage Pro2 Weather Station
Davis Instruments Vantage Pro2 Weather Station offers research-grade local weather data for networked stations, campuses, and community observatories.
The study found that the fragile X protein regulates the opening and closing of the GABA-A receptor in neurons from the brain's memory center, influencing how such neurons process information. This nuanced understanding may hold the key to developing effective therapies for fragile X syndrome.
SourceWashU Medicine·JournalCell Reports·TypeExperimental study·DateMay 17, 2022
A new study in mice identifies FXR1, a protein implicated in Fragile X syndrome, as a potential target for creating new blood pressure-lowering medicines. Deleting FXR1 in smooth muscle cells resulted in decreased diastolic blood pressure and altered vascular behavior.
A long-term study of FXTAS carriers has identified key indicators of disease progression, including cognitive decline and motor symptoms. Researchers hope to develop a validated tracking tool to monitor premutation carriers and patients with FXTAS.
SourceUniversity of California - Davis Health·JournalJournal of Neurodevelopmental Disorders·DateMar 31, 2022
A new DNA test has been developed to identify a range of hard-to-diagnose neurological and neuromuscular genetic diseases quicker and more accurately than existing tests. The test uses Nanopore sequencing technology to scan for abnormally long repeats within patients' genes, which are the hallmarks of disease.
SourceGarvan Institute of Medical Research·JournalScience Advances·TypeObservational study·DateMar 4, 2022
CalDigit TS4 Thunderbolt 4 Dock
CalDigit TS4 Thunderbolt 4 Dock simplifies serious desks with 18 ports for high-speed storage, monitors, and instruments across Mac and PC setups.
A study by UC Riverside researchers shows that reactivating the Fmr1 gene in young transgenic mice with Fragile X syndrome eliminates symptoms. This breakthrough treatment offers hope for young children living with FXS and suggests targeting early brain development may be effective.
SourceUniversity of California - Riverside·JournalNeurobiology of Disease·TypeExperimental study·DateDec 13, 2021
Researchers at Rutgers University have linked Fragile X and SHANK3 deletion syndrome, both associated with autism and health problems, to walking patterns. The study used motion-sensored sneakers to detect gait problems 15-20 years before clinical diagnosis, offering a potential framework for early intervention.
SourceRutgers University·JournalScientific Reports·DateOct 22, 2021
Researchers aim to understand language development in children with developmental language disorder (DLD) and Fragile X syndrome by examining grammar skills and executive functions. The study will gather data on a two-year developmental window, providing comprehensive insights for families and potential improvements in communication.
A new smartphone-based app, iBehavior, will be tested to improve the accuracy of data in clinical trials involving individuals with intellectual disability. The app uses ecological momentary assessment to track symptoms related to executive function, often associated with ADHD.
SourceUniversity of California - Davis Health·DateOct 8, 2021
DJI Air 3 (RC-N2)
DJI Air 3 (RC-N2) captures 4K mapping passes and environmental surveys with dual cameras, long flight time, and omnidirectional obstacle sensing.
A new study in mice reveals that fragile X treatment can incur resistance, but also identifies potential strategies to overcome this. Administering mGluR5 inhibitors at a young age and then stopping may produce lasting benefits in cognitive ability.
SourcePicower Institute at MIT·JournalFrontiers in Psychiatry·TypeExperimental study·DateSep 29, 2021
A new study found that the economic burden of caring for children with rare genetic disorders such as Fragile X syndrome and Chromosome 15 imprinting disorders is significant. Earlier diagnosis and targeted interventions could reduce yearly costs by up to $734, depending on the child's intellectual functioning.
SourceMurdoch Childrens Research Institute·JournalJournal of Autism and Developmental Disorders·TypeObservational study·DateAug 26, 2021
The article considers the ethical issues surrounding enrolling children with neurodevelopmental conditions, such as autism spectrum disorder and fragile X syndrome, in clinical trials. Parents may face difficult decisions about whether to enroll their children due to concerns about potential loss of positive aspects of their condition.
SourceThe Hastings Center·JournalIRB Ethics and Human Research·TypeContent analysis·DateAug 9, 2021
Nikon Monarch 5 8x42 Binoculars
Nikon Monarch 5 8x42 Binoculars deliver bright, sharp views for wildlife surveys, eclipse chases, and quick star-field scans at dark sites.
A phase two study found that an experimental treatment improved cognitive function and language in patients with fragile X syndrome. The treatment, BPN14770, increased levels of cyclic adenosine monophosphate (cAMP) in the brain, which is critically involved in memory formation.
SourceRush University Medical Center·JournalNature Medicine·DateApr 29, 2021
Primary cilia, acting as cell TVs to detect signals, are present in fewer numbers in mice with Fragile X syndrome. Increasing their number might lead to reversing neurodevelopmental disorders like autism and intellectual disability.
SourceUniversity of Texas Health Science Center at San Antonio·JournalStem Cell Reports·DateJul 30, 2020
Researchers discovered a range of co-existing conditions in patients with fragile X syndrome and premutation disorder. Lower FMRP levels are associated with emotional processing issues, including mood disorders, anxiety, and psychotic features. The study calls for more research on psychosis and FMRP levels, as well as greater awareness...
SourceUniversity of California - Davis Health·JournalTranslational Psychiatry·DateJun 24, 2020
Researchers found that a telehealth-delivered behavioral intervention improved language skills in youth with fragile X syndrome, while lovastatin showed no efficacy. The study used Parent-Implemented Language Intervention (PILI) to enhance parent-child interactions and promote language development.
SourceUniversity of California - Davis Health·JournalJournal of Neurodevelopmental Disorders·DateApr 21, 2020
Fluke 87V Industrial Digital Multimeter
Fluke 87V Industrial Digital Multimeter is a trusted meter for precise measurements during instrument integration, repairs, and field diagnostics.
A new test measures expressive language skills in individuals with Fragile X syndrome, helping increase participation in clinical studies aimed at improving intellectual and cognitive functioning. The test's reliability and validity were demonstrated through consistent scores across multiple administrations.
SourceNIH/Eunice Kennedy Shriver National Institute of Child Health and Human Development·JournalJournal of Neurodevelopmental Disorders·DateMar 24, 2020
A study by Michigan Medicine team discovered that repeat expansions cause neurodegenerative diseases but also found normal functions of these repeats in regulating protein production in healthy nerve cells. The research suggests a potential pathway for treating Fragile X syndrome and other disorders.
SourceMichigan Medicine - University of Michigan·JournalNature Neuroscience·DateFeb 17, 2020
A study by Anglia Ruskin University found that sleep disturbance is common among young children with neurodevelopmental disorders, including Down's syndrome, Fragile X syndrome, and Williams syndrome. The research showed that improved sleep patterns were associated with better language skills in these children.
SourceAnglia Ruskin University·JournalResearch in Developmental Disabilities·DateJan 16, 2020
Aranet4 Home CO2 Monitor
Aranet4 Home CO2 Monitor tracks ventilation quality in labs, classrooms, and conference rooms with long battery life and clear e-ink readouts.
Researchers used a grip-force test to analyze sensorimotor function in people with the FMR1 premutation, identifying subtle symptoms and potential indicators of disease progression. The study aims to improve early diagnosis and treatment for Fragile X-associated tremor/ataxia syndrome (FXTAS) in at-risk individuals.
SourceUniversity of Kansas·JournalFrontiers in Integrative Neuroscience·DateOct 17, 2019
Research suggests that early lovastatin treatment in infancy can prevent learning problems in children with Fragile X Syndrome. The drug corrected memory and learning issues in rats with the genetic alteration, with benefits persisting for months after treatment ended.
SourceUniversity of Edinburgh·JournalScience Translational Medicine·DateMay 29, 2019
A recent study by the University of Wisconsin-Madison reveals that mitochondrial dysfunction caused by a single mutation may be responsible for fragile X syndrome, autism, and other neural disorders. Researchers successfully reversed behavioral deficits in mice using a chemical treatment that restored mitochondria fusion.
SourceUniversity of Wisconsin-Madison·JournalNature Neuroscience·DateFeb 11, 2019
A new study by Carnegie Institution researchers found that defects in the Fmr1 gene can lead to difficulties in creating large protein structures, potentially contributing to autism-related disorders like fragile X syndrome. The study used fruit fly eggs to demonstrate how Fmr1 helps produce essential large proteins.
SourceCarnegie Institution for Science·JournalScience·DateAug 16, 2018
Research shows that a pharmacological strategy can alleviate multiple behavioral and cellular deficiencies in a mouse model of fragile X syndrome. Treatment with GSK6A or a similar compound could be a viable strategy for addressing cognitive and behavioral problems in fragile X syndrome.
SourceEmory Health Sciences·JournalNeuropsychopharmacology·DateJul 13, 2018
Apple iPad Pro 11-inch (M4)
Apple iPad Pro 11-inch (M4) runs demanding GIS, imaging, and annotation workflows on the go for surveys, briefings, and lab notebooks.
Scientists at Whitehead Institute have developed a modified CRISPR/Cas9 system to remove methylation tags from the FMR1 gene, restoring its expression and rescuing neurons from fragile X syndrome. This approach may prove useful for other diseases caused by abnormal methylation.
SourceWhitehead Institute for Biomedical Research·JournalCell·DateFeb 21, 2018
A study by Indiana University researchers found a link between the fragile X syndrome gene and excessive tissue growth. The discovery reveals a key biological mechanism behind the physical and mental impairments caused by fragile X syndrome, which affects 1 in 4,000 males and 1 in 6,000 females.
SourceIndiana University·JournalCell Reports·DateDec 5, 2017
Researchers found an intervention that normalizes multiple biological functions in FXS mice by targeting protein synthesis and actin dynamics. The approach offers a potential treatment for Fragile X syndrome by regulating specific proteins involved in these processes.
SourceNew York University·JournalScience Signaling·DateNov 7, 2017
A selective PDE4D inhibitor, BPN14770, has shown promise in treating Fragile X syndrome by reducing hyperarousal and improving social interactions. The treatment also exhibited long-term benefits, with no tolerance observed.
SourceKureczka/Martin Associates·JournalScientific Reports·DateNov 7, 2017
Researchers at Rockefeller University have discovered a potential new treatment for Fragile X Syndrome by targeting chromatin remodeling proteins, which play a key role in the disease's symptoms. The study found that inhibiting these proteins can alleviate symptoms and improve neuronal function.
SourceRockefeller University·JournalCell·DateNov 3, 2017
Creality K1 Max 3D Printer
Creality K1 Max 3D Printer rapidly prototypes brackets, adapters, and fixtures for instruments and classroom demonstrations at large build volume.
A new study identifies the fragile X protein's role in regulating DNA packaging, offering clues for treatment. The protein oversees a set of genes that alter how DNA is packaged, and its absence leads to fragile X syndrome.
SourceHoward Hughes Medical Institute·JournalCell·DateSep 28, 2017
Fragile X syndrome is caused by a mutation in the Fragile X Mental Retardation 1 gene, leading to permanent changes in neural circuit structure and symptoms characteristic of ASD. Research confirms FMRP's essential role in refining brain processing during early development, highlighting the need for early detection and treatment methods.
SourceVanderbilt University·JournalCurrent Biology·DateAug 25, 2017
A widely used diabetes medication, metformin, improves sociability and reduces symptomatic behaviors in adult mice with Fragile X syndrome. Researchers believe the drug could be repurposed as a therapy for this genetic disorder within a few years.
SourceUniversity of Edinburgh·JournalNature Medicine·DateMay 15, 2017
Research on fruit flies reveals that those lacking the Fragile X protein have less inhibition among their neurons, resulting in impaired information processing and increased anxiety. This finding provides valuable insights into human brain diseases and may lead to new treatments for Fragile X syndrome.
SourceVIB (the Flanders Institute for Biotechnology)·JournalCurrent Biology·DateMay 5, 2017
A Drexel University-led study found that Fragile X granules linger in the hippocampus of adult humans, expanding the age range for treatment. The study suggests that therapies targeting both dendrites and axons could be effective in treating symptoms of Fragile X syndrome and potentially other autism-related disorders.
SourceDrexel University·JournalHuman Molecular Genetics·DateMar 20, 2017
Garmin GPSMAP 67i with inReach
Garmin GPSMAP 67i with inReach provides rugged GNSS navigation, satellite messaging, and SOS for backcountry geology and climate field teams.
A new study led by TSRI researchers discovered early brain changes in patients with Fragile X syndrome, a disorder affecting brain development. The study found that the mutation on the X chromosome triggers genome-wide DNA methylation changes, which may help explain similarities with autism spectrum disorder.
SourceScripps Research Institute·JournalBrain·DateJan 30, 2017
Researchers found that glial cells, including astrocytes, are impaired by the genetic defect and involved in symptoms of fragile X syndrome. The study suggests looking beyond neuronal effects to fully understand the disease.
SourceUniversity of California - Santa Cruz·JournalBiological Psychiatry·DateOct 4, 2016
A cancer drug has improved learning and memory in mice with fragile X syndrome by coaxes neural stem cells to generate neurons critical for cognitive function. The treatment targets the MDM2 enzyme, which is overactive in FMRP-deficient cells, leading to enhanced proliferation but reduced differentiation.
SourceAmerican Association for the Advancement of Science (AAAS)·JournalScience Translational Medicine·DateApr 27, 2016
Rigol DP832 Triple-Output Bench Power Supply
Rigol DP832 Triple-Output Bench Power Supply powers sensors, microcontrollers, and test circuits with programmable rails and stable outputs.
Researchers at VIB have identified a promising target pathway for treating fragile X syndrome and autism. By targeting the APP-ADAM10 pathway, scientists may be able to ameliorate deficits associated with these conditions. The study's findings open new avenues for developing non-toxic therapeutic agents.
SourceVIB (the Flanders Institute for Biotechnology)·JournalNeuron·DateJul 16, 2015